Alpha Pro Tech (APT) Upward Path on Ebola Fears, Sucampo Pharmaceuticals (SCMP) Battle Over AMITIZA Ends Posted: October 10, 2014 |
CRWE and PolarWeb Media, LLC reported a Joint Venture agreement to engage in increasing web traffic to selected websites. CRWE will receive 50% of the revenues generated by PolarWeb Media through the use of CRWE's sites, with PolarWeb Media having the remaining 50%. PolarWeb Media, LLC will focus on driving traffic and generating ad revenues, as CRWE continues to proceed in developing additional localized news and information publication sites for to also offers business owners the power of consumer targeting advertisement on a local and national scale through offerings and deals with their restaurant, auto repair, realtor, bar, movie theater, retail business, golf course, auto dealership and any other variety of businesses existing within a community. CRWE is currently developing its CRWE-PR Network ( www.CRWE-PR.com ), a growing network of website communities, which business model is based on selling advertising to businesses targeting both locally and nationally The CRWE-PR Network has reached the 1400th community website in the U.S., associated with 3282 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, New York State, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada. According to CRWE, this joint venture will assist in monetizing its CRWE-PR network of targeted community publications, while increasing the company's shareholders value.
Together with its digital network of websites, CRWE provides and offers advertising branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com **
The World Health Organization (WHO) has warned that Ebola is now entrenched in the capital cities of all three worst-affected countries and is accelerating in almost all settings. The WHO said that the Ebola outbreak has killed more than 3,860 people, mainly in West Africa. The health of Teresa Romero, a Spanish nurse who became the first person to contract Ebola outside of West Africa has worsened and her brother said that she was now being helped with her breathing in hospital. Thomas Eric Duncan, the first person diagnosed with Ebola in the United States, died on Wednesday. According to health officials, about 48 people who had direct or indirect contact with Duncan since he arrived from Liberia on Sept. 20 are being monitored, but none have yet shown any symptoms. The Centers for Disease Control and Prevention (CDC) is working with other U.S. government agencies, the World Health Organization (WHO), and other domestic and international partners and has activated its Emergency Operations Center to help coordinate technical assistance and control activities with partners. CDC has also deployed teams of public health experts to West Africa and will continue to send experts to the affected countries. CDC and partners are taking precautions to prevent spread of Ebola within the United States. Amid fears about the spread of Ebola virus, shares of APT exchanged hands at a 52-week high levels on Thursday's trading session. APT makes protective equipment such as surgical masks and other infection control products that healthcare workers can use to prevent contracting the virus. APT said in September the hazmat protection suits would be available worldwide.
APT is the parent company of Alpha Pro Tech, Inc. and Alpha ProTech Engineered Products, Inc. APT's Alpha Pro Tech, Inc. develops, manufactures and markets innovative disposable and limited-use protective apparel products for the industrial, clean room, medical and dental markets. APT's Alpha ProTech Engineered Products, Inc. manufactures and markets a line of construction weatherization products, including building wrap and roof underlayment. More about Alpha Pro Tech Ltd. (APT) at www.alphaprotech.com. **
SCMP said that the company, R-Tech Ueno, Ltd. (RTU), Takeda Pharmaceutical Company Limited and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc., (collectively, Par) that resolves patent litigation in the United States (U.S.) related to SCMP's AMITIZA(R) (lubiprostone) 8 mcg and 24 mcg soft gelatin capsules. Under the terms of the settlement, SCMP and RTU will grant Par a non-exclusive license to market Par's generic version of lubiprostone 8 mcg soft gelatin capsule and 24 mcg soft gelatin capsule (licensed products) in the U.S. for the indications approved for AMITIZA beginning January 1, 2021, or earlier under certain circumstances. Beginning on January 1, 2021, Par will split with SCMP the gross profits of the licensed products sold during the term of the agreement, which continues until each of SCMP's patents has expired. In the event Par elects to launch an authorized generic, SCMP will supply Par under the terms of a manufacturing and supply agreement at a negotiated price. Additional details of the agreement remain confidential. Additionally, SCMP said it has received a Paragraph IV certification Notice Letter regarding an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by Dr. Reddy's Laboratories, Inc., requesting approval to market, sell and use a generic version of the 8 mcg and 24 mcg AMITIZA(R) (lubiprostone) soft gelatin capsule products. SCMP is currently reviewing the Notice Letter. By statute, if SCMP initiates a patent infringement lawsuit against Dr. Reddy's within 45 days of the Notice Date, the FDA would automatically stay approval of the Dr. Reddy's ANDA until the earlier of 30 months from the notice date or entry of a district court decision finding the patents invalid or not infringed. The product is currently protected by 15 issued patents that are listed in the FDA's Orange Book, with the latest expiring in 2027.
SCMP is focused on the development and commercialization of medicines that meet unmet medical needs of patients worldwide. Sucampo has two marketed products -- AMITIZA(R) and RESCULA(R) -- and a pipeline of product candidates in clinical development. More about Sucampo Pharmaceuticals, Inc. (SCMP) at www.sucampo.com. ** Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer
|
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Crown Equity Holdings Inc. (CRWE)
Alpha Pro Tech Ltd. (APT)
Sucampo Pharmaceuticals, Inc. (SCMP)
